'en:anti-pd-1 monoclonal antibody jnj-63723283'
(id=6896439 ; fe=en:anti-pd-1 monoclonal antibody jnj-63723283 ; type=1 ; niveau=200 ;
luminosité=25 ;
somme entrante=449 creation date=2017-06-25 touchdate=2025-06-19 20:03:49.000) ≈ 15 relations sortantes
- en:anti-pd-1 monoclonal antibody jnj-63723283 --
r_associated #0: 40 / 1 ->
en:anti-pd-1 monoclonal antibody medi0680
n1=en:anti-pd-1 monoclonal antibody jnj-63723283 | n2=en:anti-pd-1 monoclonal antibody medi0680 | rel=r_associated | relid=0 | w=40
- en:anti-pd-1 monoclonal antibody jnj-63723283 --
r_associated #0: 40 / 1 ->
en:nivolumab
n1=en:anti-pd-1 monoclonal antibody jnj-63723283 | n2=en:nivolumab | rel=r_associated | relid=0 | w=40
- en:anti-pd-1 monoclonal antibody jnj-63723283 --
r_associated #0: 39 / 0.975 ->
en:anti-pd-1 monoclonal antibody regn2810
n1=en:anti-pd-1 monoclonal antibody jnj-63723283 | n2=en:anti-pd-1 monoclonal antibody regn2810 | rel=r_associated | relid=0 | w=39
- en:anti-pd-1 monoclonal antibody jnj-63723283 --
r_associated #0: 36 / 0.9 ->
en:antigen binding
n1=en:anti-pd-1 monoclonal antibody jnj-63723283 | n2=en:antigen binding | rel=r_associated | relid=0 | w=36
- en:anti-pd-1 monoclonal antibody jnj-63723283 --
r_associated #0: 36 / 0.9 ->
en:pidilizumab
n1=en:anti-pd-1 monoclonal antibody jnj-63723283 | n2=en:pidilizumab | rel=r_associated | relid=0 | w=36
- en:anti-pd-1 monoclonal antibody jnj-63723283 --
r_associated #0: 35 / 0.875 ->
en:anti-pd-1 monoclonal antibody bgb-a317
n1=en:anti-pd-1 monoclonal antibody jnj-63723283 | n2=en:anti-pd-1 monoclonal antibody bgb-a317 | rel=r_associated | relid=0 | w=35
- en:anti-pd-1 monoclonal antibody jnj-63723283 --
r_associated #0: 35 / 0.875 ->
en:pembrolizumab
n1=en:anti-pd-1 monoclonal antibody jnj-63723283 | n2=en:pembrolizumab | rel=r_associated | relid=0 | w=35
- en:anti-pd-1 monoclonal antibody jnj-63723283 --
r_associated #0: 34 / 0.85 ->
en:ctrp agent terminology
n1=en:anti-pd-1 monoclonal antibody jnj-63723283 | n2=en:ctrp agent terminology | rel=r_associated | relid=0 | w=34
- en:anti-pd-1 monoclonal antibody jnj-63723283 --
r_associated #0: 30 / 0.75 ->
en:anti-pd1 monoclonal antibody pdr001
n1=en:anti-pd-1 monoclonal antibody jnj-63723283 | n2=en:anti-pd1 monoclonal antibody pdr001 | rel=r_associated | relid=0 | w=30
- en:anti-pd-1 monoclonal antibody jnj-63723283 --
r_associated #0: 29 / 0.725 ->
en:anti-pd-1 monoclonal antibody tsr-042
n1=en:anti-pd-1 monoclonal antibody jnj-63723283 | n2=en:anti-pd-1 monoclonal antibody tsr-042 | rel=r_associated | relid=0 | w=29
- en:anti-pd-1 monoclonal antibody jnj-63723283 --
r_associated #0: 29 / 0.725 ->
en:ctrp terminology
n1=en:anti-pd-1 monoclonal antibody jnj-63723283 | n2=en:ctrp terminology | rel=r_associated | relid=0 | w=29
- en:anti-pd-1 monoclonal antibody jnj-63723283 --
r_associated #0: 28 / 0.7 ->
en:anti-pd-1 monoclonal antibody shr-1210
n1=en:anti-pd-1 monoclonal antibody jnj-63723283 | n2=en:anti-pd-1 monoclonal antibody shr-1210 | rel=r_associated | relid=0 | w=28
- en:anti-pd-1 monoclonal antibody jnj-63723283 --
r_associated #0: 27 / 0.675 ->
anticorps
n1=en:anti-pd-1 monoclonal antibody jnj-63723283 | n2=anticorps | rel=r_associated | relid=0 | w=27
- en:anti-pd-1 monoclonal antibody jnj-63723283 --
r_associated #0: 20 / 0.5 ->
en:anti-pd-1 monoclonal antibody js001
n1=en:anti-pd-1 monoclonal antibody jnj-63723283 | n2=en:anti-pd-1 monoclonal antibody js001 | rel=r_associated | relid=0 | w=20
- en:anti-pd-1 monoclonal antibody jnj-63723283 --
r_associated #0: 2 / 0.05 ->
en:immunologic factor
n1=en:anti-pd-1 monoclonal antibody jnj-63723283 | n2=en:immunologic factor | rel=r_associated | relid=0 | w=2
| ≈ 19 relations entrantes
- en:anti-pd-1 monoclonal antibody medi0680 ---
r_associated #0: 34 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=en:anti-pd-1 monoclonal antibody medi0680 | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=34
- en:ctrp terminology ---
r_associated #0: 34 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=en:ctrp terminology | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=34
- en:anti-pd1 monoclonal antibody pdr001 ---
r_associated #0: 32 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=en:anti-pd1 monoclonal antibody pdr001 | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=32
- en:anti-pd-1 monoclonal antibody bgb-a317 ---
r_associated #0: 31 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=en:anti-pd-1 monoclonal antibody bgb-a317 | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=31
- en:anti-pd-1 monoclonal antibody regn2810 ---
r_associated #0: 31 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=en:anti-pd-1 monoclonal antibody regn2810 | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=31
- en:anti-pd-1 monoclonal antibody shr-1210 ---
r_associated #0: 30 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=en:anti-pd-1 monoclonal antibody shr-1210 | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=30
- en:antigen binding ---
r_associated #0: 30 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=en:antigen binding | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=30
- en:pidilizumab ---
r_associated #0: 30 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=en:pidilizumab | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=30
- en:anti-pd-1 monoclonal antibody tsr-042 ---
r_associated #0: 28 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=en:anti-pd-1 monoclonal antibody tsr-042 | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=28
- en:ctrp agent terminology ---
r_associated #0: 28 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=en:ctrp agent terminology | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=28
- en:pembrolizumab ---
r_associated #0: 28 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=en:pembrolizumab | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=28
- en:anti-pd-1 monoclonal antibody js001 ---
r_associated #0: 26 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=en:anti-pd-1 monoclonal antibody js001 | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=26
- en:nivolumab ---
r_associated #0: 25 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=en:nivolumab | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=25
- anticorps ---
r_associated #0: 20 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=anticorps | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=20
- Ac ---
r_associated #0: 10 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=Ac | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=10
- nivolumab ---
r_associated #0: 10 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=nivolumab | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=10
- pembrolizumab ---
r_associated #0: 10 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=pembrolizumab | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=10
- anti-corps ---
r_associated #0: 5 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=anti-corps | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=5
- en:antibody ---
r_associated #0: 5 -->
en:anti-pd-1 monoclonal antibody jnj-63723283
n1=en:antibody | n2=en:anti-pd-1 monoclonal antibody jnj-63723283 | rel=r_associated | relid=0 | w=5
|